Clarus Therapeutics (OTCMKTS:CRXTQ – Get Rating) and Anavex Life Sciences (NASDAQ:AVXL – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

0.3% of Clarus Therapeutics shares are held by institutional investors. Comparatively, 31.2% of Anavex Life Sciences shares are held by institutional investors. 5.3% of Clarus Therapeutics shares are held by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

This is a summary of recent ratings for Clarus Therapeutics and Anavex Life Sciences, as provided by MarketBeat.com.

This table compares Clarus Therapeutics and Anavex Life Sciences’ net margins, return on equity and return on assets.

This table compares Clarus Therapeutics and Anavex Life Sciences’ revenue, earnings per share and valuation.

Clarus Therapeutics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Clarus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Clarus Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Anavex Life Sciences beats Clarus Therapeutics on 7 of the 13 factors compared between the two stocks.

(Get Rating)

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

(Get Rating)

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Receive News & Ratings for Clarus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.